Table of Contents 2
List of Tables 5
List of Figures 5
Emergent BioSolutions Inc. Spshot 6
Emergent BioSolutions Inc. Overview 6
Key Information 6
Key Facts 6
Emergent BioSolutions Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Emergent BioSolutions Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combition Treatment Modalities 13
Emergent BioSolutions Inc. - Pipeline Products Glance 14
Emergent BioSolutions Inc. - Late Stage Pipeline Products 14
Filing rejected/Withdrawn Products/Combition Treatment Modalities 14
Emergent BioSolutions Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combition Treatment Modalities 15
Phase I Products/Combition Treatment Modalities 16
Emergent BioSolutions Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combition Treatment Modalities 17
Discovery Products/Combition Treatment Modalities 18
Emergent BioSolutions Inc. - Drug Profiles 19
coagulation factor IX (recombint) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AV-7909 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
otlertuzumab 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PreviThrax 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ES-414 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
5-E3 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
antihemophilic factor (recombint) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ES-210 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ES-301 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ES-306 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EV-035 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GC-072 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MVA-RSV 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MVAH-5HA 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombint Protein to Inhibit CD19 and CD3 for B-Cell Lymphoma 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MonoClol Antibody for Ebola and Marburg Infections 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Recombint Protein to Target HER-2 and CD3 for Cancer 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Recombint Protein to Target RON and CD3 for Cancer 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaccines for Undisclosed Indication 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Emergent BioSolutions Inc. - Pipeline Alysis 42
Emergent BioSolutions Inc. - Pipeline Products by Target 42
Emergent BioSolutions Inc. - Pipeline Products by Route of Administration 44
Emergent BioSolutions Inc. - Pipeline Products by Molecule Type 45
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action 46
Emergent BioSolutions Inc. - Recent Pipeline Updates 48
Emergent BioSolutions Inc. - Dormant Projects 57
Emergent BioSolutions Inc. - Dormant Projects 57
Emergent BioSolutions Inc. - Discontinued Pipeline Products 58
Discontinued Pipeline Product Profiles 58
Anthrivig 58
Immune Globulin 58
Leucotropin 58
PEP-35 58
TST-10088 58
Emergent BioSolutions Inc. - Company Statement 59
Emergent BioSolutions Inc. - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68